Current projects

We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.

We are looking for D/P's in the following categories:

ID # Required D/P's Enrolled D/P's Remaining D/P's Inclusion Criteria
293358 15 0 15 Serum samples from Gardnerella Vaginalis Positive Donors
292896 10 0 10 Prospective Serum Collection Protocol from RPR Positive Subjects
292748 100 20 80 Pre-Selected Plasma Samples from Inventory from Smallpox Vaccinated DPs (born before 1970)
292590 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Nasal Swab, Pharyngeal Swab, Vaginal Swab, Rectal Swab, Lesion Swab, Saliva Sample and/or Blood Samples from a positive or suspected positive D/Ps with Monkeypox
292576 20 6 14 Prospective Collection of SARS-CoV-2 Positive NP Samples
292415 30 19 11 Pre-Selected Gonorrhea Positive Samples from Inventory (Urine)
291821 200 75 125 Pre-Selected HBsAg Samples with Viral Load from Inventory
291489 10 10 0 Pre-Selected RPR Positive Samples from Inventory with Specific Titer
291273 10 10 0 Prospective Whole Blood Collection from Healthy (HxV Negative) D/Ps - TZC0025991/SACQ_0002779_1
291078 5 5 0 Pre-Selected RPR Positive Samples from Inventory
290559 20 20 0 Negative Serum samples for HCV Panels_Q 16961
290371 100 70 30 Pre-Selected Pre-COVID (2019) Normal Serum/Serum SST Samples from Inventory
289863 15 15 0 Pre-Selected SARS-CoV-2 Positive Samples From Inventory
289663 5 0 5 Pre-Selected HBsAg Positive Samples with Viral Load from Inventory
289635 8 8 0 HIV-1 Positive Stability Study
288929 10 9 1 Negative Serum samples for HCV Panels dilution_Q 16961
287443 4 0 4 HxV Negative Pooled K3EDTA Plasma from Inventory - TZC0022637/ SRF_0002958
286853 5 5 0 Pre-Selected HBsAg Positive Samples with Viral Load from Inventory
286151 600 388 212 Pre-Selected HCV/HBV Plasma Samples from Inventory.
285982 50 50 0 Pre-Selected Samples from D/Ps with High Risk for STD Infection (MSM Population)
285449 1 3 -2 Double Spun Plasma from Healthy (HxV Negative) D/Ps - SRF_0002946 / SACQ_0002743
285286 5 6 -1 Pre-Selected Pediatric Samples from Inventory
284340 200 19 181 Pre-Selected HCV Positive Samples from Inventory (18SUST025)
284339 200 10 190 Pre-Selected HCV Positive Samples from Inventory (19SUST057)
284338 200 27 173 Pre-Selected T. Pallidum and/or RPR Positive Samples from Inventory (18SUST025)
284337 200 60 140 Pre-Selected HBsAg Positive Samples from Inventory (18SUST025)
284336 200 10 190 Pre-Selected HCV Positive Samples from Inventory (19SUST056)
284059 20 20 0 Whole Blood from Healthy Individuals
283651 50 0 50 Fresh Whole Blood from HIV-1 Positive Individuals
283533 10 10 0 Fresh Whole Blood from HIV-1 Positive Individuals
283190 200 113 87 Protocol No. LIA-STI-250 - cobas CT/NG/MG Nucleic acid test for use on the cobas Liat System: Feasibility Performance Evaluation
283183 5 5 0 K2EDTA Plasma and PDB (Plasma Depleted Blood) from Healthy (HxV Negative) D/Ps - TZC0016030 / SRF_0002935 / SACQ_0002726
283000 8 5 3 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load and Genotype
282948 100 9 91 Nasal and Nasopharyngeal swabs from SARS-CoV-2 (Omicron) Positive Donors
282803 5 4 1 Fresh Whole Blood from HIV-1 Positive Individuals
282800 10 0 10 High Volume Serum from HxV Donors
282613 100 0 100 Rapigen-001 - Clinical Study Protocol - BIOCREDIT COVID-19 Ag Home Test Nasal (Puerto Rico)
282612 100 25 75 Rapigen-001 - Clinical Study Protocol - BIOCREDIT COVID-19 Ag Home Test Nasal (Miami)
282610 10000 0 10000 A Multi Site, Longitudinal, Prospective Sample Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
282442 24 24 0 Female Vaginal Sample Collection Protocol for Panel Development
282386 100 100 0 Prospective Whole Blood Collection from HxV Negative donors (Age 60+)
281873 30 3 27 Pre-Selected Gonorrhea Positive Samples from Inventory (Urine)
281868 30 3 27 Pre-Selected Chlamydia Positive Samples from Inventory (Urine)
281776 200 205 -5 Oropharyngeal Swabs from Healthy Donors
281675 20000 2904 17096 Customer Samples kept in Biorepository (CHIV Study 2011, Universiti of Miami, Zawadzki, Cassandra )
281672 50 50 0 Pre-Selected Samples from D/Ps with High Risk Factors for Syphilis
281523 50 50 0 Prospective Whole Blood Collection from HxV Negative donors (Age 60+)
281517 7 7 0 Normal Healthy DP's collected in Whole Blood with Specific WBC Count - SRF_0002902
- 1 donor with WBC Count 3,000-5,000/uL
- 1 donor with WBC Count 5,000-6,000/uL
- 4 donor with WBC Count 9,000-10,000/uL
- 1 donor with WBC Count 11,000-14,000/uL
281243 25 25 0 Pre-Selected HIV-2 Samples from Inventory
280543 6 2 4 Pre-Selected HIV and HCV Positive Plasma Samples from Inventory with High Viral Load
280533 20 20 0 Prospective Urine Collection from Healthy Donors
279827 6 0 6 Pre-Selected HCV RNA Negative Serum Samples from Inventory
278992 5 5 0 Pre-Selected SARS-CoV-2 Positive Samples From Inventory
278976 100 112 -12 Prospective Sars-Cov-2 , Flu A, Flu B and RSV Samples Collection_TCZ0006755 / SRF_0002812
277324 30 14 16 Pre-Selected RPR Positive Samples from Inventory
277194 5 5 0 Pre-Selected Na Citrate plasma HxV Negative Samples From Inventory
276588 6 6 0 RMS SARS-CoV-2 Samples for Heat Inactivation
276033 200 187 13 Collection protocol for Panel construction (Custom HIV-1 panels, Q_16975)
272609 5 1 4 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
272143 400 0 400 Pre-Selected HBV Positive Samples from Inventory with Viral Load and Genotype
271914 100 8 92 COVID-19 Testing; Private Office
271841 25 17 8 Pre-Selected anti-HBs Samples from Inventory
271463 800 0 800 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Las Vegas
271462 800 0 800 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Northridge
267417 50 46 4 Prescreaning collection for JR 236653 (HIV Positive DPs, Viral Load 1000-8000)
267180 1500 776 724 Prospective Healthy Subject Blood Collection Protocol
266931 120 17 103 PAS-19SUST053 Testing HBV VL (Abbott & Hologic)
266866 120 26 94 Protocol: FD-001 - Clinical Evaluation of the Fosun COVID-19 Ag Home Test In Symptomatic and Asymptomatic Subjects
263501 100 29 71 Protocol: ZPT-001 - Clinical Performance of the Zepto SARS-CoV-2 IgG Self Test In Subjects who are Symptomatic and Asymptomatic from COVID-19 Infection
261154 800 1892 -1092 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation
259067 100 50 50 Clinical Evaluation of the Visby Medical Respiratory Health Test for the Detection and Differentiation of SARS-CoV-2, Influenza A and Influenza B Viral RNA - Clinical Protocol TP-000547
251350 100 30 70 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
243774 60 0 60 Pre-Selected BKV and EBV Negative Plasma Samples from Inventory - SRF_0002565
243767 450 0 450 Pre-Selected BKV and EBV Positive Plasma and Urine Samples from Inventory - SRF_0002565
242729 300 299 1 Vaginal Sample Collection Protocol - Donors with Vaginitis Symptoms
242206 5000 26091 -21091 COVID-19 Testing
239950 1000 40 960 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami
239188 500 0 500 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
236653 5 2 3 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
233218 150 8 142 IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing
231203 100 103 -3 Clinical Evaluation of Visby Medical Personal PCR Women’s Sexual Health Test for the Detection of CT, GC and TV using self-collected Vaginal Swabs - Protocol TP-000669
231202 53 53 0 Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516
230530 20000 1295 18705 Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel)
228548 100 102 -2 Remnant VZV Samples (IGG Negative)
228201 20000 466 19534 Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF)
227994 130 5 125 PAS-19SUST054 - HCV
227993 130 1 129 PAS-19SUST052 - HBV
227992 130 10 120 PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay
226001 100 39 61 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
225611 10000 0 10000 A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
225101 1000 9 991 COVID-19 Testing; Private Office
224701 360 0 360 cX8-COV-549: Classic Repro Protocol
224514 600 76 524 Initiative to Screen Potential Study Candidates (SUST)
219607 1000 13 987 COVID-19 Testing; Private Office
213622 2500 0 2500 Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
210071 2500 555 1945 Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
208168 1000 111 889 COVID-19 Testing; Private Office
201758 130 48 82 PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
200508 1000 60 940 COVID-19 Testing; Private Office
198391 500 0 500 Prospective Healthy Subject Blood Collection Protocol
195775 20000 1380 18620 Customer Samples kept in Biorepository from HBcT2 [JRID#93116]
190737 5000 34 4966 SARS-CoV-2 Survey (PT)
184026 700 542 158 SARS-CoV-2 RNA Hologic Testing
182696 1000 355 645 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections
178076 130 79 51 PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
175792 10000 116 9884 COVID-19 Testing; Tu Cara me Sue
175398 10000 552 9448 COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd
175121 1000 27 973 CBC Initiative
174026 1000 122 878 COVID-19 Testing; Private Office
173768 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects
173505 20 20 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
172886 1000 1018 -18 COVID-19 Testing; Private Office
169711 400 398 2 SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva
169440 300 110 190 Remnant Pregnancy Samples
169439 100 258 -158 Remnant HSV Samples
168867 1000 350 650 COVID-19 Testing; Private Office
168078 50 2 48 Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva)
165868 1000 156 844 COVID-19 Testing; Private Office
163904 1000 1002 -2 COVID-19 Testing; Private Office
155679 30 313 -283 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
154904 10000 40 9960 COVID-19 Testing; Private Office
154536 1000 458 542 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 500 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
153900 10000 31301 -21301 COVID-19 Testing, Florida Department of Health
152854 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
152825 5000 106637 -101637 COVID-19 Testing
152672 5000 40 4960 Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs
152331 5000 1654 3346 COVID-19 Testing
151681 5000 3 4997 Refer to Processing Instructions @ Attachment Tab
151476 1 0 1 HIV Group and Subtype Testing
149547 5000 220 4780 Refer to Processing Instructions @ Attachment Tab
TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB
148791 5000 32 4968 Refer to Processing Instructions @ Attachment Tab
145574 5000 90 4910 Refer to Processing Instructions @ Attachment Tab
144620 5000 41 4959 Refer to Processing Instructions @ Attachment Tab
144001 100 825 -725 Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM):
- 50 samples from subjects with the ages of 2 through 12 years of age AND
- 50 samples from subjects with the ages of 13 through 21 years of age
- Gender: Male or Female
- Minimum Volume: 1.5 mL (1.2 mL's)
- Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection.
143401 1500 1158 342 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 3000 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
142755 5000 90 4910 Refer to Processing Instructions @ Attachment Tab
141914 1000 7 993 HIV Initiative
141493 5000 45 4955 HCV Viral Load and Genotype Survey (PT)
141491 5000 18 4982 HBV Viral Load Survey (PT)
141490 5000 45 4955 HIV Viral Load Survey (PT)
140923 5000 80 4920 Refer to Processing Instructions @ Attachment Tab
140922 5000 45 4955 Refer to Processing Instructions @ Attachment Tab
140530 5000 10 4990 Rubella IgG (AAB - PT)
140528 5000 6 4994 ToRCH (AAB - PT)
139409 5000 90 4910 Pregnancy (PT)
137933 5000 0 5000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
137683 930 235 695 Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations
136025 300 357 -57 EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM)
134182 100 80 20 HBV/Mayaro Samples from Colombia
133225 200 274 -74 Prospective HCV Positive serum collection
129688 200 123 77 EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia
129538 1000 309 691 RPR Initiative
128402 1000 64 936 CBC Initiative
124266 5000 143 4857 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire
122931 5000 1535 3465 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
122654 5000 171 4829 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland
120851 140 26 114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
120409 300 84 216 Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population
109382 100 32 68 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
109381 300 6 294 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
108692 1000 977 23 HxV Testing Initiative
102772 50 26 24 Random Cadaveric Samples
102419 1000 456 544 Samples on hold for future shipments to China
98830 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples
98084 1000 577 423 CBC Qualifying Job Request
96278 195 185 10 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
96055 40 1755 -1715 Hologic Panels for HIV and HCV
94841 500 1 499 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR
93116 700 755 -55 Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis
80997 5000 428 4572 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
79734 100 0 100 Prospective Zika Screening and Longitudinal Sample Collection Protocol
78138 300 140 160 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
78137 300 414 -114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
74261 10000 0 10000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
68258 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
66495 200 225 -25 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue
63869 1 2 -1 Negative Material for Panel Member
63868 1000 555 445 Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau
56717 20000 0 20000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples
55075 10000 28 9972 Beta HCG Matched Set Prospective Blood Collection Protocol
54664 200 148 52 Random Cadaveric Samples
38626 300 143 157 Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications:
·50 x Alcoholic liver disease
·30 x Autoimmune hepatitis
·30 x Fatty liver disease
·30 x Non-alcoholic Steatohepatitis (NASH)
·30 x Primary Biliary Cirrhosis (PBC)
27615 15000 633 14367 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World
26761 10000 482 9518 HIV Positive Time Stability Whole Blood Collection Protocol
10694 3000 2234 766 HCV Longitudinal Prospective Blood Collection Protocol
10693 3000 369 2631 HBV Multi-Point Prospective Blood Collection Protocol
8568 300 1648 -1348 Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV)



BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.

You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.



Contact us to learn more